1 min read
Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
